

Market Applicability													
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Dihydroergotamine Mesylate (DHE)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Dihydroergotamine Mesylate (DHE) injection

APPROVAL CRITERIA

Requests for intravenous, intramuscular or subcutaneous dihydroergotamine (DHE) injection may be approved if the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to two preferred triptan agents;

Preferred agents: sumatriptan tablet, naratriptan tablet

AND

- II. Individual is age 18 or older; **AND**
- III. Individual is using for acute treatment of migraine with aura; **AND**
- IV. Individual meets the following International Headache Society (IHS) diagnostic criteria (ICHD-3):
 - A. Individual has 2 or more headache attacks; **AND**
 - B. Individual has 1 or more of the following fully reversible aura symptoms:
 1. Visual (for example, flickering lights, spots or lines); **OR**
 2. Sensory (for example, pins and needles, numbness); **OR**
 3. Speech and/or language (for example, aphasia); **OR**
 4. Motor (for example, weakness); **OR**
 5. Brainstem (for example, ataxia or vertigo); **OR**
 6. Retinal (for example, blindness);

AND

- C. Individual has at least three of the following six characteristics:
 1. At least 1 aura symptom develops gradually over 5 or more minutes; **OR**
 2. Two (2) or more aura symptoms occur in succession; **OR**

PAGE 1 of 4 05/29/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0396-19

Market Applicability													
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

3. Each individual aura symptom lasts 5 to 60 minutes; **OR**
4. At least 1 aura symptom is unilateral; **OR**
5. At least one aura symptom is positive (scintillations and pins and needles are examples of positive symptoms of aura); **OR**
6. The aura is accompanied, or followed within 60 minutes, by headache;

AND

- D. Individual's headache is not attributed to another disorder (for example, ischemia stroke or transient ischemic attack);

OR

- V. Individual is age 18 or older; **AND**
- VI. Individual is using for acute treatment of migraine without aura meeting the following IHS diagnostic criteria (ICHD-3):
 - A. Individual has 5 or more headache attacks; **AND**
 - B. Individual's headaches last 4 to 72 hours (untreated or unsuccessfully treated); **AND**
 - C. Individual's headache has 2 or more of the following characteristics:
 1. Unilateral location; **OR**
 2. Pulsating quality; **OR**
 3. Moderate or severe pain intensity; **OR**
 4. Aggravation by or causing avoidance of routine physical activity (for example, walking or climbing stairs);

AND

- D. Individual's headache is accompanied by 1 or more of the following:
 1. Nausea, vomiting or both; **OR**
 2. Photophobia or phonophobia;

AND

- E. Individual's headache is not attributed to another headache disorder.

OR

- VII. Individual is age 18 or older; **AND**
- VIII. Individual is using for acute treatment of cluster headache episodes in an adult meeting the following IHS diagnostic criteria (ICHD-3):
 - A. Individual has 5 or more headache attacks; **AND**
 - B. Individual has severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15 to 180 minutes if untreated; **AND**
 - C. Individual's headache is accompanied by 1 or both of the following:
 1. One (1) or more of the following symptoms or signs, ipsilateral to the headache:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability													
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

- a. Conjunctival injection and/or lacrimation; **OR**
- b. Nasal congestion and/or rhinorrhea; **OR**
- c. Eyelid edema; **OR**
- d. Forehead and facial sweating; **OR**
- e. Forehead and facial flushing; **OR**
- f. Miosis and/or ptosis;

OR

- 2. A sense of restlessness or agitation;

AND

- D. Attacks have a frequency from 1 every other day to 8 per day for more than half of the time the disorder is active;

AND

- E. Individual's headache is not attributed to another headache disorder;

OR

- IX. Individual has status migrainosis or rebound withdrawal type of headaches;

OR

- X. Individual has only received narcotics for severe migraine or cluster headaches;

OR

- XI. Individual is unresponsive to prior use of triptans for severe migraine or cluster headache.

Requests for intravenous, intramuscular or subcutaneous dihydroergotamine (DHE) injection may **not** be approved if the following criteria met:

- I. Individual is using concomitantly with a potent CYP3A4 inhibitor (including ritonavir, nelfinavir, idinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole); **OR**
- II. Individual has a diagnosis of ischemic heart disease (angina pectoris, history of myocardial infarction, documented silent ischemia) or has clinical symptoms consistent with coronary artery vasospasm including Prinzmetal's variant angina; **OR**
- III. Individual has uncontrolled hypertension; **OR**
- IV. Individual has hemiplegic or basilar migraine; **OR**
- V. Individual has used a 5-HT₁ agonist (such as sumatriptan), ergotamine-containing or ergot-type medication or methysergide within the previous 24 hours; **OR**
- VI. Individual has peripheral arterial disease; **OR**

PAGE 3 of 4 05/29/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0396-19

Market Applicability													
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

VII. Individual has severely impaired hepatic or renal function.

Note: DHE has a black box warning regarding serious and/or life-threatening peripheral ischemia if co-administered with a potent CYP3A4 inhibitor, including protease inhibitors and macrolide antibiotics. Concomitant use is contraindicated.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 4, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018; 38(1):1-211. Available from: <https://www.ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf>. Accessed: October 4, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.